{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 26,
  "pageCount": 58,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "data_table",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The chart highlights factors directly related to commercial attractiveness in green.",
  "elementsJson": [
    "headline_text",
    "bar_chart_horizontal",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/26",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-26",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Ability to solve unmet clinical needs is our top priority. In addition, we would also consider if this drug would be a value-add to our current portfolio.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-c9d7bbc587df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.037,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Pharmas' key considerations when prioritizing drugs for clinical development",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aae98f9b-b4a2-4e3a-af8f-e4e74cbe519a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.037,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "Note: *Survey question (for pharmas): What are the key considerations when your company prioritizes a therapeutic area or product for R&D? Source: L.E.K. survey, interviews and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42c84e6d-ee6b-4c05-9feb-b9542f469157",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.25,
        "y": 0.83
      },
      "kind": "legend",
      "text": "Commercial attractiveness directly related",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f14e689-81ba-49b1-83ed-516e7bd44854",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Percent of respondents: 85",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-d15adccd26e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "quote",
      "text": "Market feedback: quotes from CEOs and VPs of Chinese biopharma companies regarding prioritization criteria.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d868ff6-254e-4dcc-8395-359a694133b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "To solve unmet clinical needs is our top priority. In addition, we would also consider if this drug would be a value-add to our current portfolio, and if we can leverage our advantage of commercial ability to launch the product efficiently ... - CEO, a Chinese biopharma, Feb. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-ce13e1d7e8cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.926,
        "x": 0.037,
        "y": 0.065
      },
      "kind": "title",
      "text": "Respondents also think that commercial attractiveness related factors are quite important when making comprehensive considerations for drug prioritization",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d24391b3-5032-4ad9-8a2a-2221bffbdef2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.448,
        "x": 0.037,
        "y": 0.035
      },
      "kind": "title",
      "text": "Increasing Focus of More Commercially Attractive Development Areas",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1512ae7b-24b1-4a70-b2a0-d9824d3168c5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Percent of respondents",
      "numberRaw": "85",
      "numberKind": "plain",
      "actionTitle": "Respondents also think that commercial attractiveness related factors are quite important when making comprehensive considerations for drug prioritization",
      "calloutText": "Ability to solve unmet clinical needs is our top priority. In addition, we would also consider if this drug would be a value-add to our current portfolio.",
      "numberScale": null,
      "numberValue": 85,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}